Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

  • Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes
on page 1 showing 20 out of 345 results from 1 sources
http://web.expasy.org/cellosaurus/CVCL_1D46

Cite this Ximbio Cat# 152111, RRID:CVCL_1D46
Organism: Homo sapiens
Disease: Invasive ductal carcinoma, not otherwise specified
Category: Cancer cell line
Comment: Sequence variation: Heterozygous for PIK3CA p.His1047Arg (from parent cell line). Sequence variation: Homozygous for TP53 p.Leu194Phe (from parent cell line). Derived from metastatic site: Pleural effusion.

  • From Current Category

http://web.expasy.org/cellosaurus/CVCL_0088

Cite this RRID:CVCL_0088
Organism: Homo sapiens
Disease: Invasive ductal carcinoma, not otherwise specified
Category: Cancer cell line
Comment: Sequence variation: Heterozygous for PIK3CA p.Glu545Lys (from parent cell line). Derived from metastatic site: Pleural effusion.

  • From Current Category

http://web.expasy.org/cellosaurus/CVCL_0178

Cite this ATCC Cat# HTB-19, RRID:CVCL_0178
Organism: Homo sapiens
Disease: Invasive ductal carcinoma, not otherwise specified
Category: Cancer cell line
Comment: Group: Triple negative breast cancer (TNBC) cell line. Part of: Cancer Cell Line Encyclopedia (CCLE) project. Part of: EGFR genetic alteration cell panel (ATCC TCP-1027). Part of: ICBP43 breast cancer cell line panel. Part of: KuDOS 95 cell line panel. Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982). Part of: PI3K genetic alteration cell panel (ATCC TCP-1028). Doubling time: 70 hours (PubMed=25984343). Microsatellite instability: Stable (MSS) (PubMed=12661003; Sanger). Omics: CNV analysis. Omics: Deep exome analysis. Omics: Deep RNAseq analysis. Omics: DNA methylation analysis. Omics: miRNA expression profiling. Omics: Protein expression by reverse-phase protein arrays. Omics: shRNA library screening. Omics: SNP array analysis. Omics: Transcriptome analysis. Discontinued: ATCC; CRL-7912.

  • From Current Category

http://web.expasy.org/cellosaurus/CVCL_0178

Cite this CLS Cat# 300130/p656_BT-20, RRID:CVCL_0178
Organism: Homo sapiens
Disease: Invasive ductal carcinoma, not otherwise specified
Category: Cancer cell line
Comment: Group: Triple negative breast cancer (TNBC) cell line. Part of: Cancer Cell Line Encyclopedia (CCLE) project. Part of: EGFR genetic alteration cell panel (ATCC TCP-1027). Part of: ICBP43 breast cancer cell line panel. Part of: KuDOS 95 cell line panel. Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982). Part of: PI3K genetic alteration cell panel (ATCC TCP-1028). Doubling time: 70 hours (PubMed=25984343). Microsatellite instability: Stable (MSS) (PubMed=12661003; Sanger). Omics: CNV analysis. Omics: Deep exome analysis. Omics: Deep RNAseq analysis. Omics: DNA methylation analysis. Omics: miRNA expression profiling. Omics: Protein expression by reverse-phase protein arrays. Omics: shRNA library screening. Omics: SNP array analysis. Omics: Transcriptome analysis. Discontinued: ATCC; CRL-7912.

  • From Current Category

http://web.expasy.org/cellosaurus/CVCL_0178

Cite this KCLB Cat# 60061, RRID:CVCL_0178
Organism: Homo sapiens
Disease: Invasive ductal carcinoma, not otherwise specified
Category: Cancer cell line
Comment: Group: Triple negative breast cancer (TNBC) cell line. Part of: Cancer Cell Line Encyclopedia (CCLE) project. Part of: EGFR genetic alteration cell panel (ATCC TCP-1027). Part of: ICBP43 breast cancer cell line panel. Part of: KuDOS 95 cell line panel. Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982). Part of: PI3K genetic alteration cell panel (ATCC TCP-1028). Doubling time: 70 hours (PubMed=25984343). Microsatellite instability: Stable (MSS) (PubMed=12661003; Sanger). Omics: CNV analysis. Omics: Deep exome analysis. Omics: Deep RNAseq analysis. Omics: DNA methylation analysis. Omics: miRNA expression profiling. Omics: Protein expression by reverse-phase protein arrays. Omics: shRNA library screening. Omics: SNP array analysis. Omics: Transcriptome analysis. Discontinued: ATCC; CRL-7912.

  • From Current Category

http://web.expasy.org/cellosaurus/CVCL_0178

Cite this NCBI_Iran Cat# C434, RRID:CVCL_0178
Organism: Homo sapiens
Disease: Invasive ductal carcinoma, not otherwise specified
Category: Cancer cell line
Comment: Group: Triple negative breast cancer (TNBC) cell line. Part of: Cancer Cell Line Encyclopedia (CCLE) project. Part of: EGFR genetic alteration cell panel (ATCC TCP-1027). Part of: ICBP43 breast cancer cell line panel. Part of: KuDOS 95 cell line panel. Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982). Part of: PI3K genetic alteration cell panel (ATCC TCP-1028). Doubling time: 70 hours (PubMed=25984343). Microsatellite instability: Stable (MSS) (PubMed=12661003; Sanger). Omics: CNV analysis. Omics: Deep exome analysis. Omics: Deep RNAseq analysis. Omics: DNA methylation analysis. Omics: miRNA expression profiling. Omics: Protein expression by reverse-phase protein arrays. Omics: shRNA library screening. Omics: SNP array analysis. Omics: Transcriptome analysis. Discontinued: ATCC; CRL-7912.

  • From Current Category

http://web.expasy.org/cellosaurus/CVCL_0178

Cite this ATCC Cat# CRL-7912, RRID:CVCL_0178
Organism: Homo sapiens
Disease: Invasive ductal carcinoma, not otherwise specified
Category: Cancer cell line
Comment: Group: Triple negative breast cancer (TNBC) cell line. Part of: Cancer Cell Line Encyclopedia (CCLE) project. Part of: EGFR genetic alteration cell panel (ATCC TCP-1027). Part of: ICBP43 breast cancer cell line panel. Part of: KuDOS 95 cell line panel. Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982). Part of: PI3K genetic alteration cell panel (ATCC TCP-1028). Doubling time: 70 hours (PubMed=25984343). Microsatellite instability: Stable (MSS) (PubMed=12661003; Sanger). Omics: CNV analysis. Omics: Deep exome analysis. Omics: Deep RNAseq analysis. Omics: DNA methylation analysis. Omics: miRNA expression profiling. Omics: Protein expression by reverse-phase protein arrays. Omics: shRNA library screening. Omics: SNP array analysis. Omics: Transcriptome analysis. Discontinued: ATCC; CRL-7912.

  • From Current Category

http://web.expasy.org/cellosaurus/CVCL_0179

Cite this KCLB Cat# 60062, RRID:CVCL_0179
Organism: Homo sapiens
Disease: Invasive ductal carcinoma, not otherwise specified
Category: Cancer cell line
Comment: Part of: AKT genetic alteration cell panel (ATCC TCP-1029). Part of: Cancer Cell Line Encyclopedia (CCLE) project. Part of: EGFR genetic alteration cell panel (ATCC TCP-1027). Part of: ERK genetic alteration cell panel (ATCC TCP-1033). Part of: ICBP43 breast cancer cell line panel. Part of: KuDOS 95 cell line panel. Part of: MD Anderson Cell Lines Project. Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982). Doubling time: 3.5 days (PubMed=9671407); 78 hours (PubMed=25984343); ~100 hours (DSMZ). Microsatellite instability: Stable (MSS) (PubMed=23671654; Sanger). Sequence variation: Heterozygous for MAPK1 p.His61Gln (ATCC). Omics: Array-based CGH. Omics: CNV analysis. Omics: Deep exome analysis. Omics: Deep phosphoproteome analysis. Omics: Deep proteome analysis. Omics: Deep RNAseq analysis. Omics: DNA methylation analysis. Omics: Genome sequenced. Omics: Metabolome analysis. Omics: miRNA expression profiling. Omics: Protein expression by reverse-phase protein arrays. Omics: shRNA library screening. Omics: SNP array analysis. Omics: Transcriptome analysis. Discontinued: ATCC; CRL-7913.

  • From Current Category

http://web.expasy.org/cellosaurus/CVCL_0179

Cite this NCBI_Iran Cat# C435, RRID:CVCL_0179
Organism: Homo sapiens
Disease: Invasive ductal carcinoma, not otherwise specified
Category: Cancer cell line
Comment: Part of: AKT genetic alteration cell panel (ATCC TCP-1029). Part of: Cancer Cell Line Encyclopedia (CCLE) project. Part of: EGFR genetic alteration cell panel (ATCC TCP-1027). Part of: ERK genetic alteration cell panel (ATCC TCP-1033). Part of: ICBP43 breast cancer cell line panel. Part of: KuDOS 95 cell line panel. Part of: MD Anderson Cell Lines Project. Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982). Doubling time: 3.5 days (PubMed=9671407); 78 hours (PubMed=25984343); ~100 hours (DSMZ). Microsatellite instability: Stable (MSS) (PubMed=23671654; Sanger). Sequence variation: Heterozygous for MAPK1 p.His61Gln (ATCC). Omics: Array-based CGH. Omics: CNV analysis. Omics: Deep exome analysis. Omics: Deep phosphoproteome analysis. Omics: Deep proteome analysis. Omics: Deep RNAseq analysis. Omics: DNA methylation analysis. Omics: Genome sequenced. Omics: Metabolome analysis. Omics: miRNA expression profiling. Omics: Protein expression by reverse-phase protein arrays. Omics: shRNA library screening. Omics: SNP array analysis. Omics: Transcriptome analysis. Discontinued: ATCC; CRL-7913.

  • From Current Category

http://web.expasy.org/cellosaurus/CVCL_0179

Cite this ATCC Cat# CRL-7913, RRID:CVCL_0179
Organism: Homo sapiens
Disease: Invasive ductal carcinoma, not otherwise specified
Category: Cancer cell line
Comment: Part of: AKT genetic alteration cell panel (ATCC TCP-1029). Part of: Cancer Cell Line Encyclopedia (CCLE) project. Part of: EGFR genetic alteration cell panel (ATCC TCP-1027). Part of: ERK genetic alteration cell panel (ATCC TCP-1033). Part of: ICBP43 breast cancer cell line panel. Part of: KuDOS 95 cell line panel. Part of: MD Anderson Cell Lines Project. Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982). Doubling time: 3.5 days (PubMed=9671407); 78 hours (PubMed=25984343); ~100 hours (DSMZ). Microsatellite instability: Stable (MSS) (PubMed=23671654; Sanger). Sequence variation: Heterozygous for MAPK1 p.His61Gln (ATCC). Omics: Array-based CGH. Omics: CNV analysis. Omics: Deep exome analysis. Omics: Deep phosphoproteome analysis. Omics: Deep proteome analysis. Omics: Deep RNAseq analysis. Omics: DNA methylation analysis. Omics: Genome sequenced. Omics: Metabolome analysis. Omics: miRNA expression profiling. Omics: Protein expression by reverse-phase protein arrays. Omics: shRNA library screening. Omics: SNP array analysis. Omics: Transcriptome analysis. Discontinued: ATCC; CRL-7913.

  • From Current Category

http://web.expasy.org/cellosaurus/CVCL_0179

Cite this ATCC Cat# HTB-20, RRID:CVCL_0179
Organism: Homo sapiens
Disease: Invasive ductal carcinoma, not otherwise specified
Category: Cancer cell line
Comment: Part of: AKT genetic alteration cell panel (ATCC TCP-1029). Part of: Cancer Cell Line Encyclopedia (CCLE) project. Part of: EGFR genetic alteration cell panel (ATCC TCP-1027). Part of: ERK genetic alteration cell panel (ATCC TCP-1033). Part of: ICBP43 breast cancer cell line panel. Part of: KuDOS 95 cell line panel. Part of: MD Anderson Cell Lines Project. Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982). Doubling time: 3.5 days (PubMed=9671407); 78 hours (PubMed=25984343); ~100 hours (DSMZ). Microsatellite instability: Stable (MSS) (PubMed=23671654; Sanger). Sequence variation: Heterozygous for MAPK1 p.His61Gln (ATCC). Omics: Array-based CGH. Omics: CNV analysis. Omics: Deep exome analysis. Omics: Deep phosphoproteome analysis. Omics: Deep proteome analysis. Omics: Deep RNAseq analysis. Omics: DNA methylation analysis. Omics: Genome sequenced. Omics: Metabolome analysis. Omics: miRNA expression profiling. Omics: Protein expression by reverse-phase protein arrays. Omics: shRNA library screening. Omics: SNP array analysis. Omics: Transcriptome analysis. Discontinued: ATCC; CRL-7913.

  • From Current Category

http://web.expasy.org/cellosaurus/CVCL_0179

Cite this KCB Cat# KCB 2011115YJ, RRID:CVCL_0179
Organism: Homo sapiens
Disease: Invasive ductal carcinoma, not otherwise specified
Category: Cancer cell line
Comment: Part of: AKT genetic alteration cell panel (ATCC TCP-1029). Part of: Cancer Cell Line Encyclopedia (CCLE) project. Part of: EGFR genetic alteration cell panel (ATCC TCP-1027). Part of: ERK genetic alteration cell panel (ATCC TCP-1033). Part of: ICBP43 breast cancer cell line panel. Part of: KuDOS 95 cell line panel. Part of: MD Anderson Cell Lines Project. Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982). Doubling time: 3.5 days (PubMed=9671407); 78 hours (PubMed=25984343); ~100 hours (DSMZ). Microsatellite instability: Stable (MSS) (PubMed=23671654; Sanger). Sequence variation: Heterozygous for MAPK1 p.His61Gln (ATCC). Omics: Array-based CGH. Omics: CNV analysis. Omics: Deep exome analysis. Omics: Deep phosphoproteome analysis. Omics: Deep proteome analysis. Omics: Deep RNAseq analysis. Omics: DNA methylation analysis. Omics: Genome sequenced. Omics: Metabolome analysis. Omics: miRNA expression profiling. Omics: Protein expression by reverse-phase protein arrays. Omics: shRNA library screening. Omics: SNP array analysis. Omics: Transcriptome analysis. Discontinued: ATCC; CRL-7913.

  • From Current Category

http://web.expasy.org/cellosaurus/CVCL_0179

Cite this BCRJ Cat# 0353, RRID:CVCL_0179
Organism: Homo sapiens
Disease: Invasive ductal carcinoma, not otherwise specified
Category: Cancer cell line
Comment: Part of: AKT genetic alteration cell panel (ATCC TCP-1029). Part of: Cancer Cell Line Encyclopedia (CCLE) project. Part of: EGFR genetic alteration cell panel (ATCC TCP-1027). Part of: ERK genetic alteration cell panel (ATCC TCP-1033). Part of: ICBP43 breast cancer cell line panel. Part of: KuDOS 95 cell line panel. Part of: MD Anderson Cell Lines Project. Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982). Doubling time: 3.5 days (PubMed=9671407); 78 hours (PubMed=25984343); ~100 hours (DSMZ). Microsatellite instability: Stable (MSS) (PubMed=23671654; Sanger). Sequence variation: Heterozygous for MAPK1 p.His61Gln (ATCC). Omics: Array-based CGH. Omics: CNV analysis. Omics: Deep exome analysis. Omics: Deep phosphoproteome analysis. Omics: Deep proteome analysis. Omics: Deep RNAseq analysis. Omics: DNA methylation analysis. Omics: Genome sequenced. Omics: Metabolome analysis. Omics: miRNA expression profiling. Omics: Protein expression by reverse-phase protein arrays. Omics: shRNA library screening. Omics: SNP array analysis. Omics: Transcriptome analysis. Discontinued: ATCC; CRL-7913.

  • From Current Category

http://web.expasy.org/cellosaurus/CVCL_0179

Cite this BCRC Cat# 60359, RRID:CVCL_0179
Organism: Homo sapiens
Disease: Invasive ductal carcinoma, not otherwise specified
Category: Cancer cell line
Comment: Part of: AKT genetic alteration cell panel (ATCC TCP-1029). Part of: Cancer Cell Line Encyclopedia (CCLE) project. Part of: EGFR genetic alteration cell panel (ATCC TCP-1027). Part of: ERK genetic alteration cell panel (ATCC TCP-1033). Part of: ICBP43 breast cancer cell line panel. Part of: KuDOS 95 cell line panel. Part of: MD Anderson Cell Lines Project. Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982). Doubling time: 3.5 days (PubMed=9671407); 78 hours (PubMed=25984343); ~100 hours (DSMZ). Microsatellite instability: Stable (MSS) (PubMed=23671654; Sanger). Sequence variation: Heterozygous for MAPK1 p.His61Gln (ATCC). Omics: Array-based CGH. Omics: CNV analysis. Omics: Deep exome analysis. Omics: Deep phosphoproteome analysis. Omics: Deep proteome analysis. Omics: Deep RNAseq analysis. Omics: DNA methylation analysis. Omics: Genome sequenced. Omics: Metabolome analysis. Omics: miRNA expression profiling. Omics: Protein expression by reverse-phase protein arrays. Omics: shRNA library screening. Omics: SNP array analysis. Omics: Transcriptome analysis. Discontinued: ATCC; CRL-7913.

  • From Current Category

http://web.expasy.org/cellosaurus/CVCL_0179

Cite this CLS Cat# 300131/p705_BT-474, RRID:CVCL_0179
Organism: Homo sapiens
Disease: Invasive ductal carcinoma, not otherwise specified
Category: Cancer cell line
Comment: Part of: AKT genetic alteration cell panel (ATCC TCP-1029). Part of: Cancer Cell Line Encyclopedia (CCLE) project. Part of: EGFR genetic alteration cell panel (ATCC TCP-1027). Part of: ERK genetic alteration cell panel (ATCC TCP-1033). Part of: ICBP43 breast cancer cell line panel. Part of: KuDOS 95 cell line panel. Part of: MD Anderson Cell Lines Project. Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982). Doubling time: 3.5 days (PubMed=9671407); 78 hours (PubMed=25984343); ~100 hours (DSMZ). Microsatellite instability: Stable (MSS) (PubMed=23671654; Sanger). Sequence variation: Heterozygous for MAPK1 p.His61Gln (ATCC). Omics: Array-based CGH. Omics: CNV analysis. Omics: Deep exome analysis. Omics: Deep phosphoproteome analysis. Omics: Deep proteome analysis. Omics: Deep RNAseq analysis. Omics: DNA methylation analysis. Omics: Genome sequenced. Omics: Metabolome analysis. Omics: miRNA expression profiling. Omics: Protein expression by reverse-phase protein arrays. Omics: shRNA library screening. Omics: SNP array analysis. Omics: Transcriptome analysis. Discontinued: ATCC; CRL-7913.

  • From Current Category

http://web.expasy.org/cellosaurus/CVCL_0179

Cite this ICLC Cat# HTL00008, RRID:CVCL_0179
Organism: Homo sapiens
Disease: Invasive ductal carcinoma, not otherwise specified
Category: Cancer cell line
Comment: Part of: AKT genetic alteration cell panel (ATCC TCP-1029). Part of: Cancer Cell Line Encyclopedia (CCLE) project. Part of: EGFR genetic alteration cell panel (ATCC TCP-1027). Part of: ERK genetic alteration cell panel (ATCC TCP-1033). Part of: ICBP43 breast cancer cell line panel. Part of: KuDOS 95 cell line panel. Part of: MD Anderson Cell Lines Project. Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982). Doubling time: 3.5 days (PubMed=9671407); 78 hours (PubMed=25984343); ~100 hours (DSMZ). Microsatellite instability: Stable (MSS) (PubMed=23671654; Sanger). Sequence variation: Heterozygous for MAPK1 p.His61Gln (ATCC). Omics: Array-based CGH. Omics: CNV analysis. Omics: Deep exome analysis. Omics: Deep phosphoproteome analysis. Omics: Deep proteome analysis. Omics: Deep RNAseq analysis. Omics: DNA methylation analysis. Omics: Genome sequenced. Omics: Metabolome analysis. Omics: miRNA expression profiling. Omics: Protein expression by reverse-phase protein arrays. Omics: shRNA library screening. Omics: SNP array analysis. Omics: Transcriptome analysis. Discontinued: ATCC; CRL-7913.

  • From Current Category

http://web.expasy.org/cellosaurus/CVCL_0179

Cite this DSMZ Cat# ACC-64, RRID:CVCL_0179
Organism: Homo sapiens
Disease: Invasive ductal carcinoma, not otherwise specified
Category: Cancer cell line
Comment: Part of: AKT genetic alteration cell panel (ATCC TCP-1029). Part of: Cancer Cell Line Encyclopedia (CCLE) project. Part of: EGFR genetic alteration cell panel (ATCC TCP-1027). Part of: ERK genetic alteration cell panel (ATCC TCP-1033). Part of: ICBP43 breast cancer cell line panel. Part of: KuDOS 95 cell line panel. Part of: MD Anderson Cell Lines Project. Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982). Doubling time: 3.5 days (PubMed=9671407); 78 hours (PubMed=25984343); ~100 hours (DSMZ). Microsatellite instability: Stable (MSS) (PubMed=23671654; Sanger). Sequence variation: Heterozygous for MAPK1 p.His61Gln (ATCC). Omics: Array-based CGH. Omics: CNV analysis. Omics: Deep exome analysis. Omics: Deep phosphoproteome analysis. Omics: Deep proteome analysis. Omics: Deep RNAseq analysis. Omics: DNA methylation analysis. Omics: Genome sequenced. Omics: Metabolome analysis. Omics: miRNA expression profiling. Omics: Protein expression by reverse-phase protein arrays. Omics: shRNA library screening. Omics: SNP array analysis. Omics: Transcriptome analysis. Discontinued: ATCC; CRL-7913.

  • From Current Category

http://web.expasy.org/cellosaurus/CVCL_0258

Cite this DSMZ Cat# ACC-386, RRID:CVCL_0258
Organism: Homo sapiens
Disease: Chronic eosinophilic leukemia, not otherwise specified
Category: Cancer cell line
Comment: Part of: Cancer Cell Line Encyclopedia (CCLE) project. Doubling time: ~60 hours (DSMZ). Microsatellite instability: Stable (MSS) (Sanger). Omics: Deep exome analysis. Omics: DNA methylation analysis. Omics: SNP array analysis. Omics: Transcriptome analysis.

  • From Current Category

http://web.expasy.org/cellosaurus/CVCL_0258

Cite this ECACC Cat# 94042252, RRID:CVCL_0258
Organism: Homo sapiens
Disease: Chronic eosinophilic leukemia, not otherwise specified
Category: Cancer cell line
Comment: Part of: Cancer Cell Line Encyclopedia (CCLE) project. Doubling time: ~60 hours (DSMZ). Microsatellite instability: Stable (MSS) (Sanger). Omics: Deep exome analysis. Omics: DNA methylation analysis. Omics: SNP array analysis. Omics: Transcriptome analysis.

  • From Current Category

http://web.expasy.org/cellosaurus/CVCL_0258

Cite this RCB Cat# RCB0641, RRID:CVCL_0258
Organism: Homo sapiens
Disease: Chronic eosinophilic leukemia, not otherwise specified
Category: Cancer cell line
Comment: Part of: Cancer Cell Line Encyclopedia (CCLE) project. Doubling time: ~60 hours (DSMZ). Microsatellite instability: Stable (MSS) (Sanger). Omics: Deep exome analysis. Omics: DNA methylation analysis. Omics: SNP array analysis. Omics: Transcriptome analysis.

  • From Current Category

  1. Resource Identification Portal Resources

    Welcome to the RRID Resources search. From here you can search through a compilation of resources used by RRID and see how data is organized within our community.

  2. Navigation

    You are currently on the Community Resources tab looking through categories and sources that RRID has compiled. You can navigate through those categories from here or change to a different tab to execute your search through. Each tab gives a different perspective on data.

  3. Logging in and Registering

    If you have an account on RRID then you can log in from here to get additional features in RRID such as Collections, Saved Searches, and managing Resources.

  4. Searching

    Here is the search term that is being executed, you can type in anything you want to search for. Some tips to help searching:

    1. Use quotes around phrases you want to match exactly
    2. You can manually AND and OR terms to change how we search between words
    3. You can add "-" to terms to make sure no results return with that term in them (ex. Cerebellum -CA1)
    4. You can add "+" to terms to require they be in the data
    5. Using autocomplete specifies which branch of our semantics you with to search and can help refine your search
  5. Save Your Search

    You can save any searches you perform for quick access to later from here.

  6. Query Expansion

    We recognized your search term and included synonyms and inferred terms along side your term to help get the data you are looking for.

  7. Collections

    If you are logged into RRID you can add data records to your collections to create custom spreadsheets across multiple sources of data.

  8. Sources

    Here are the sources that were queried against in your search that you can investigate further.

  9. Categories

    Here are the categories present within RRID that you can filter your data on

  10. Subcategories

    Here are the subcategories present within this category that you can filter your data on

  11. Further Questions

    If you have any further questions please check out our FAQs Page to ask questions and see our tutorials. Click this button to view this tutorial again.

X